Feed - Buzzberg

12:00
Jul 28 ◎

INCY FY2026 Q2 Watch

Incyte Corporation (INCY) FY2026 Q2 Earnings Call

NVS SNDX HALO PRLD INCY ▾

Suki

Novartis's settlement with Incyte reduced Incyte's expense base in the prior year, indicating a financial relationship between the companies.

"The year-over-year increase reflects a lower expense base in the second quarter of 2025, resulting from the Novartis settlement of $242 million."

NVS WATCH

Pablo

Syndax is running the Niktimbo IPF study; its data readout will be a key catalyst for a potential opt-in decision by Incyte.

"The disclosure of the data, since they're conducting the study, will be done by Syndex."

SNDX WATCH

Pablo

Collaborating with Halozyme to optimize the subcutaneous formulation of 9A9 using their enhanced delivery technology adds optionality and could improve patient experience for the drug.

"We recently entered a global collaboration and license agreement with Halozyme to evaluate the subcutaneous formulation of 9A9 using enhanced technology."

HALO WATCH

Pablo

Incyte has a collaboration with Prelude for JAK2V617F assets, but owns the decision on whether to opt in based on data coming from Prelude.

"On the Prelude Agreement, obviously those programs are managed by Prelude."

PRLD WATCH

Bill

The overall guidance tone is confident with raised revenue guidance for the year, reflecting broad-based strength across the portfolio and a stronger pipeline.

"Taken together, Insight is no longer dependent on one asset, catalyst or blockbuster. We now have a solid core business, a series of near-term launches and a more mature late-stage pipeline supporting multiple avenues for future growth."

INCY WATCH

Bill

Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting. — With a third of the market, Incyte faces direct competition from Gilead's momelotinib and possibly others; maintaining this share is key to the heme-onc portfolio's growth.

"We currently hold approximately one third of the third line plus market."

GILD WATCH

HIGH

12:00
Apr 28 ◎

INCY FY2026 Q1 Watch

Incyte Corporation (INCY) FY2026 Q1 Earnings Call

INCY ▾

Bill

Management conveys strong confidence in the company's trajectory, with net sales up 20%, a strong pipeline, and multiple upcoming regulatory milestones. The tone is optimistic, and they reaffirm full-year guidance while highlighting the potential of new product launches.

"We're off to a strong start in 2026, with net sales up 20% year over year, driven by strong demand across our entire portfolio."

INCY WATCH

HIGH

13:00
Feb 10 ◎

INCY FY2025 Q4 Watch

Incyte Corporation (INCY) FY2025 Q4 Earnings Call

INCY ▾

Bill

Management guided revenues up 10-13% and emphasized multiple late-stage pipeline catalysts (Monjuvi, Povacitinib, KRAS G12D, etc.) that could triple the top line. The long-term strategy to replace the Jackify franchise with diversified core growth underpins the bullish tone.

"Our core business excluding Jackify has the potential to be as large as Jackify is today by 2030."

INCY WATCH

HIGH

Feed — Buzzberg